Matsushita Y - Search Results

1

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.

Tateishi K, Nakamura T, Juratli TA, Williams EA, Matsushita Y, Miyake S, Nishi M, Miller JJ, Tummala SS, Fink AL, Lelic N, Koerner MVA, Miyake Y, Sasame J, Fujimoto K, Tanaka T, Minamimoto R, Matsunaga S, Mukaihara S, Shuto T, Taguchi H, Udaka N, Murata H, Ryo A, Yamanaka S, Curry WT, Dias-Santagata D, Yamamoto T, Ichimura K, Batchelor TT, Chi AS, Iafrate AJ, Wakimoto H, Cahill DP. Tateishi K, et al. Among authors: matsushita y. Clin Cancer Res. 2019 Jul 15;25(14):4375-4387. doi: 10.1158/1078-0432.CCR-18-4144. Epub 2019 Apr 11. Clin Cancer Res. 2019. PMID: 30975663 Free PMC article.

2

Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.

Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S. Ohno M, et al. Among authors: matsushita y. Brain Tumor Pathol. 2012 Oct;29(4):183-91. doi: 10.1007/s10014-012-0113-1. Epub 2012 Jul 13. Brain Tumor Pathol. 2012. PMID: 22790483

3

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.

Okita Y, Narita Y, Miyakita Y, Ohno M, Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T, Shibui S. Okita Y, et al. Among authors: matsushita y. Int J Oncol. 2012 Oct;41(4):1325-36. doi: 10.3892/ijo.2012.1564. Epub 2012 Jul 20. Int J Oncol. 2012. PMID: 22825915

4

Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.

Ohno M, Narita Y, Miyakita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Shibui S. Ohno M, et al. Among authors: matsushita y. Brain Tumor Pathol. 2013 Oct;30(4):224-32. doi: 10.1007/s10014-013-0140-6. Epub 2013 Mar 14. Brain Tumor Pathol. 2013. PMID: 23494632

5

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K. Arita H, et al. Among authors: matsushita y. Acta Neuropathol. 2013 Aug;126(2):267-76. doi: 10.1007/s00401-013-1141-6. Epub 2013 Jun 14. Acta Neuropathol. 2013. PMID: 23764841

6

TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas.

Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Shibui S, Ichimura K. Arita H, et al. Among authors: matsushita y. Acta Neuropathol. 2013 Dec;126(6):939-41. doi: 10.1007/s00401-013-1203-9. Epub 2013 Oct 31. Acta Neuropathol. 2013. PMID: 24174165 No abstract available.

7

Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.

Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K. Arita H, et al. Among authors: matsushita y. Brain Tumor Pathol. 2015 Jan;32(1):22-30. doi: 10.1007/s10014-014-0186-0. Epub 2014 Apr 19. Brain Tumor Pathol. 2015. PMID: 24748374

8

Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas.

Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K. Takami H, et al. Among authors: matsushita y. Brain Pathol. 2015 May;25(3):256-65. doi: 10.1111/bpa.12173. Epub 2014 Oct 29. Brain Pathol. 2015. PMID: 25040820 Free PMC article.

9

Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.

Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. Nakamura T, et al. Among authors: matsushita y. Neuropathol Appl Neurobiol. 2016 Apr;42(3):279-90. doi: 10.1111/nan.12259. Epub 2015 Jul 20. Neuropathol Appl Neurobiol. 2016. PMID: 26111727

10

Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.

Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, Yoshida A, Fukushima S, Takami H, Ichimura K, Shibui S. Ohno M, et al. Among authors: matsushita y. Jpn J Clin Oncol. 2016 Jan;46(1):31-9. doi: 10.1093/jjco/hyv170. Epub 2015 Nov 24. Jpn J Clin Oncol. 2016. PMID: 26603354

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,218 results

Search Page

Filters